JP2007533733A5 - - Google Patents

Download PDF

Info

Publication number
JP2007533733A5
JP2007533733A5 JP2007509061A JP2007509061A JP2007533733A5 JP 2007533733 A5 JP2007533733 A5 JP 2007533733A5 JP 2007509061 A JP2007509061 A JP 2007509061A JP 2007509061 A JP2007509061 A JP 2007509061A JP 2007533733 A5 JP2007533733 A5 JP 2007533733A5
Authority
JP
Japan
Prior art keywords
drug
betahistine
pharmaceutical composition
medicament
antipsychotic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2007509061A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007533733A (ja
Filing date
Publication date
Priority claimed from IL16159504A external-priority patent/IL161595A0/xx
Application filed filed Critical
Priority claimed from PCT/IL2005/000440 external-priority patent/WO2005101979A2/en
Publication of JP2007533733A publication Critical patent/JP2007533733A/ja
Publication of JP2007533733A5 publication Critical patent/JP2007533733A5/ja
Pending legal-status Critical Current

Links

JP2007509061A 2004-04-22 2005-04-21 食物摂取管理の方法 Pending JP2007533733A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IL16159504A IL161595A0 (en) 2004-04-22 2004-04-22 Betahistine as a weight management agent
US67029005P 2005-04-12 2005-04-12
PCT/IL2005/000440 WO2005101979A2 (en) 2004-04-22 2005-04-21 Method of food intake management

Publications (2)

Publication Number Publication Date
JP2007533733A JP2007533733A (ja) 2007-11-22
JP2007533733A5 true JP2007533733A5 (enExample) 2008-05-29

Family

ID=35197421

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007509061A Pending JP2007533733A (ja) 2004-04-22 2005-04-21 食物摂取管理の方法

Country Status (10)

Country Link
US (5) US20060084686A1 (enExample)
EP (1) EP1737454A4 (enExample)
JP (1) JP2007533733A (enExample)
KR (1) KR20060134041A (enExample)
BR (1) BRPI0506807A (enExample)
CA (1) CA2553309A1 (enExample)
EA (1) EA200601414A1 (enExample)
IL (1) IL176793A0 (enExample)
NO (1) NO20063221L (enExample)
WO (1) WO2005101979A2 (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2553309A1 (en) * 2004-04-22 2005-11-03 Mor Research Applications Ltd. Method of food intake management
US20080051440A1 (en) * 2004-04-22 2008-02-28 Mor Research Applications Ltd. Compositions for weight management
US7728015B2 (en) * 2004-04-22 2010-06-01 Mor Research Applications Ltd. Compositions for weight management
WO2007020079A2 (en) * 2005-08-17 2007-02-22 Synthon B.V. Orally disintegratable simvastatin tablets
US8242148B2 (en) * 2005-12-23 2012-08-14 Nelson Erik B Treatment methods employing histamine H3 receptor antagonists, including betahistine
CN101472476B (zh) * 2006-06-16 2013-10-30 泰拉科斯有限公司 毒蕈碱型受体m1拮抗剂在制备治疗肥胖症的药物中的应用
US8748419B2 (en) * 2006-06-16 2014-06-10 Theracos, Inc. Treating obesity with muscarinic receptor M1 antagonists
US20080033019A1 (en) * 2006-08-07 2008-02-07 Duke University Cholesterol lowering drug combination
US20160331729A9 (en) * 2007-04-11 2016-11-17 Omeros Corporation Compositions and methods for prophylaxis and treatment of addictions
WO2008128126A1 (en) * 2007-04-11 2008-10-23 Omeros Corporation Compositions and methods for prophylaxis and treatment of addictions
US11241420B2 (en) 2007-04-11 2022-02-08 Omeros Corporation Compositions and methods for prophylaxis and treatment of addictions
WO2008157094A1 (en) * 2007-06-13 2008-12-24 Cypress Bioscience, Inc. Improving the tolerability of mirtazapine and a second active by using them in combination
US8586634B2 (en) 2007-06-15 2013-11-19 University Of Florida Research Foundation, Inc. Therapeutic compounds
ES2419204T3 (es) 2008-05-27 2013-08-19 The University Of Melbourne Métodos para tratar a mamíferos con disfunciones de la trompa de Eustaquio
WO2011009012A1 (en) * 2009-07-15 2011-01-20 Columbia University METHODS OF SUPPRESSING APPETITE BY THE ADMINISTRATION OF ANTAGONISTS OF THE SEROTONIN HTR1a or HTR2b RECEPTORS OR INHIBITORS OF TPH2
US20110021507A1 (en) * 2009-07-22 2011-01-27 Theracos, Inc. Inhibiting antipsychotic-induced weight gain
BR112012011561A2 (pt) * 2009-10-13 2017-01-10 Nestec Sa sistemas para avaliação da ingestão dietética e métodos de uso do mesmo
HUE043963T2 (hu) 2009-12-04 2019-09-30 Alkermes Pharma Ireland Ltd Morfinán származékok gyógyszer-túladagolás kezelésére
US20110143704A1 (en) 2009-12-14 2011-06-16 William Lorentz Specialized dial a chip
EP2608670B1 (en) 2010-08-23 2018-10-31 Alkermes Pharma Ireland Limited Methods for treating antipsychotic-induced weight gain
US9211293B2 (en) 2011-12-15 2015-12-15 Alkermes Pharma Ireland Limited Opioid agonist antagonist combinations
US20140072936A1 (en) * 2012-09-07 2014-03-13 Patrick D. Herron Method of Tracking Consumption and Associated Effects
ES2770978T3 (es) 2013-05-24 2020-07-06 Alkermes Pharma Ireland Ltd Análogos de morfanos y morfinanos y métodos de uso
US9656961B2 (en) 2013-05-24 2017-05-23 Alkermes Pharma Ireland Limited Methods for treating depressive symptoms
RU2540911C2 (ru) * 2013-06-11 2015-02-10 Государственное бюджетное образовательное учреждение высшего профессионального образования "Воронежская государственная медицинская академия им. Н.Н. Бурденко" Министерства здравоохранения Российской Федерации Способ коррекции синдрома ночной еды у пациентов с тревожно-депрессивными расстройствами
DE102015202695A1 (de) * 2015-02-13 2016-08-18 Carl Zeiss Smt Gmbh Prüfvorrichtung sowie Verfahren zum Prüfen eines Spiegels
DK3698791T3 (da) * 2017-02-02 2024-01-15 Otolanum Ag Intranasal sammensætning, der omfatter betahistin
WO2022101444A1 (en) 2020-11-12 2022-05-19 Alkermes Pharma Ireland Limited Immediate release multilayer tablet
AU2024230525A1 (en) * 2023-02-28 2025-10-09 Biohaven Therapeutics Ltd. Methods for treating obsessive compulsive related disorders, tic disorders and glutamate excitotoxicity related disorders

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1577871A (en) 1976-05-28 1980-10-29 Unimed Inc Prevention of myocardial infarction
JPS55154915A (en) * 1979-05-21 1980-12-02 Jiyan Sadeia Shieruki Medicine mold
US6117855A (en) 1996-10-07 2000-09-12 Merck Sharp & Dohme Ltd. Use of a NK-1 receptor antagonist and an antidepressant and/or an anti-anxiety agent
DE69911058T2 (de) 1998-12-23 2004-06-03 G.D. Searle Llc, Chicago Kombinationen einem ibat inhibitor und einem mtp inhibitor für kardiovaskuläre indikationen
US6403806B1 (en) 1998-12-23 2002-06-11 Maxim Pharmaceuticals, Inc. Synthesis of histamine dihydrochloride
IT1309591B1 (it) 1999-03-05 2002-01-24 Formenti Farmaceutici Spa Composizioni a rilascio controllato di betaistina.
JP2003500353A (ja) * 1999-05-19 2003-01-07 アストラゼネカ・アクチエボラーグ 処置方法
AU2001250365A1 (en) * 2000-03-08 2001-09-17 Awd Pharma Gmbh & Co. Kg Pharmaceutical preparations containing saccharose fatty acid esters for controlling the release of active ingredients
US6607748B1 (en) * 2000-06-29 2003-08-19 Vincent Lenaerts Cross-linked high amylose starch for use in controlled-release pharmaceutical formulations and processes for its manufacture
WO2002087556A2 (en) 2001-04-11 2002-11-07 Atherogenics, Inc. Probucol monoesters and their use to increase plasma hdl cholesterol levels and improve hdl functionality
US20030162824A1 (en) 2001-11-12 2003-08-28 Krul Elaine S. Methods of treating or preventing a cardiovascular condition using a cyclooxygenase-1 inhibitor
US20040110803A1 (en) 2002-09-13 2004-06-10 Hossein Dovlatabadi Methods and compositions for the use of D-malic acid to decrease serum triglyceride, cholesterol and lipoprotein levels
US20050222175A1 (en) 2004-03-31 2005-10-06 Dhanoa Dale S New piperidinylamino-thieno[2,3-D] pyrimidine compounds
CA2553309A1 (en) * 2004-04-22 2005-11-03 Mor Research Applications Ltd. Method of food intake management
US7728015B2 (en) * 2004-04-22 2010-06-01 Mor Research Applications Ltd. Compositions for weight management
US20080051440A1 (en) * 2004-04-22 2008-02-28 Mor Research Applications Ltd. Compositions for weight management
WO2006023703A2 (en) 2004-08-20 2006-03-02 Cypress Bioscience, Inc. Method for treating sleep related breathing disorders

Similar Documents

Publication Publication Date Title
RU2355387C2 (ru) Трансдермальный гранисетрон
EP3731870B1 (en) Liquid oral formulations for pde v inhibitors
JP2014528474A5 (enExample)
CA2450366A1 (en) Controlled heat induced rapid delivery of pharmaceuticals from skin depot
ES2762113T3 (es) Métodos de proporcionar terapia de pérdida de peso en pacientes con depresión mayor
JP2010530431A5 (enExample)
TW201136916A (en) New uses
Quinn et al. Novel methods of drug administration for the treatment and care of older patients
JP2015524444A5 (enExample)
JP2018520382A (ja) 薬物の投与及び混合のための装置及び方法、並びにそのための適切な技法のトレーニング
AU2017379247A1 (en) Pharmaceutical dosage forms containing TASK-1 and TASK-3 channel inhibitors, and the use of same in breathing disorder therapy
US20200093737A1 (en) Pharmaceutical dosage forms containing task-1 and task-3 channel inhibitors, and the use of same in breathing disorder therapy
WO2013173317A1 (en) TREATMENT OF OBSTRUCTIVE SLEEP APNEA WITH α2-ADRENERGIC RECEPTOR AGONISTS
US20160287549A1 (en) Novel methods for treating neurodegenerative diseases
JP2005511120A (ja) 皮膚デポからの医薬品の制御された熱誘導迅速送達
US20090149518A1 (en) Pharmaceutical for protection of motor nerve in patient with amyotrophic lateral sclerosis
MY151230A (en) Novel method
JP2009539877A5 (enExample)
EP1772149A1 (en) Drug for prevention or treatment of diabetes
JP2022508217A (ja) Task-1およびtask-3チャンネル阻害剤を含有する医薬投薬形態の製造方法、ならびに呼吸障害治療におけるその使用
JP2009506043A5 (enExample)
CN102772414A (zh) 治疗潮红的s-米氮平
WO2024107115A1 (en) Methods of compounding an injectable drug into a film or wafer and systems thereof
JP3948480B2 (ja) いびき又は睡眠時の呼吸障害の予防・治療剤
WO2008120617A1 (ja) クローン病に伴う腸管狭窄の進展抑制用医薬組成物